• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 25, 2016

View Archived Issues

EMDAC makes room for new addition from Novo Nordisk to diabetes arsenal

Despite a few FDA qualms, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) embraced a fixed combination diabetes drug that couples a titratable basal insulin product with a glucagon-like peptide-1 (GLP-1) receptor agonist that has only a few recommended effective doses. Read More

Investors a-GOG: Oxigene's phase II with Avastin/CA4P combo scores OS in ovarian

With a pivotal phase II/III trial to start "in the next several weeks," Oxigene Inc. CEO William Schwieterman told BioWorld Today that the just-published results on CA4P (fosbretabulin) paired with approved cancer therapy Avastin (bevacizumab, Roche AG) in recurrent ovarian cancer "are potentially huge for the field" of vascular-targeted therapy in solid tumors. "While [CA4P] is old, we have a new plan and a new story," he said. Read More

Niche HIV drug moves closer to market with phase III hit

Preliminary data from a pivotal phase III test of experimental HIV drug ibalizumab, developed by Taimed Biologics Inc. and slated for marketing by Theratechnologies Inc., helped 82.5 percent of patients receiving it meet the study's primary endpoint of a decrease of ≥ 0.5 log10 in viral load following a seven-day treatment period. Theratechnologies shares (TSX:TH) climbed 8.5 percent to close at C$2.55 (US$1.94) on Tuesday. Read More

Chance finding revives struggling firm, failed drug in newco Iceni

LONDON – There are two repurposings for the price of one in the launch today of Iceni Pharmaceuticals Ltd., with the former DNA vaccines company transmuting into a cancer specialist and bringing cilengitide, an integrin inhibitor that previously failed in a phase III trial in glioma, back into the clinic as a treatment for multiple myeloma. Read More

China's ICT comes out of stealth with CAR T trial results in leukemia

SHANGHAI – Dozens of Chinese biopharmas have entered the CAR T race, but Shanghai-based Innovative Cellular Therapeutics Co. Ltd., (ICT), also known as Sidansai in Chinese, is angling to be the front-runner. Read More

Japan's FGC planning $50M venture fund aimed at biotech

TOKYO – Fintech Global Capital LLC (FGC), a Japanese venture fund, is looking to raise about $50 million this year, mainly from institutional investors, to be spent on biotech companies in 2017. Read More

Financings

Relief Therapeutics SA, of Geneva, received an initial tranche of funding from Global Emerging Markets as part of a planned €2.5 million (US$2.8 million) series A round to support planning for clinical development activities for lead drug atexakin alfa. Read More

Other news to note

Alimera Sciences Ltd., of Atlanta, said real-world data show that the majority of diabetic macular edema patients who received Iluvien (fluocinolone acetonide 190 mcg intravitreal implant in applicator) in routine clinical practice gained or maintained vision at 12 months. Read More

In the clinic

Boehringer Ingelheim GmbH, of Ingelheim, Germany, presented results from a phase II study in Crohn's disease at Digestive Disease Week in San Diego, showing that risankizumab (formerly BI 655066), a compound recently licensed by Abbvie Inc., of North Chicago, was found to be more effective than placebo in patients with moderately to severely active Crohn's. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe